Business Wire
-
October 27, 2026
Nidec Files Suit for Damages against Former Executives
Oct. 27, 2026 08:10 UTC Nidec Files Suit for Damages against Former Executives KYOTO, Japan–(BUSINESS WIRE)– As announced in the press release, “Nidec Receives an Investigation Report from the Executive Responsibility Investigation Committee,” dated October 16, 2026, Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (“Nidec” or the “Company”) received an investigation report (the “Investigation Report”) issued by the Executive Responsibility Investigation Committee (the “Investigation Committee”) on the date. After, based on the Investigation Report, contemplating the necessity to file a lawsuit against its former and current executives, the Company has decided today to file a suit for damages against the following former executives (the “Lawsuit”): 1. Former Directors – Messrs. […]
-
October 27, 2026
Fujifilm Introduces instax mini Evo 2™ Hybrid Instant Camera
Oct. 27, 2026 02:00 UTC Fujifilm Introduces instax mini Evo 2™ Hybrid Instant Camera New camera features and a refreshed app take the instax Evo™ line to the next level VALHALLA, N.Y.–(BUSINESS WIRE)– FUJIFILM North America Corporation, Imaging Division, today announced the launch of its instax mini Evo 2™ (hereafter Evo 2) hybrid instant camera, along with its enhanced instax mini Evo™ smartphone app. “The instax Evo™ line remains an incredibly popular part of the instax™ product family, so it made perfect sense to take everything about the original Evo that made it great and enhance it even further,” said Bing Liem, division president, Imaging Division, FUJIFILM North America Corporation. […]
-

October 27, 2026
SHOJO MANGA INFINITY: Moto Hagio, Ryoko Yamagishi and Waki Yamato – A Major Exhibition Tracing the Expanding Possibilities of Shojo Manga
Oct. 27, 2026 01:00 UTC SHOJO MANGA INFINITY: Moto Hagio, Ryoko Yamagishi and Waki Yamato – A Major Exhibition Tracing the Expanding Possibilities of Shojo Manga The National Art Center, Tokyo | October 28, 2026 – February 8, 2027 TOKYO–(BUSINESS WIRE)– To commemorate its 20th anniversary, The National Art Center, Tokyo presents SHOJO MANGA INFINITY: Moto Hagio, Ryoko Yamagishi and Waki Yamato, a major exhibition bringing together three pioneering artists who transformed the possibilities of shojo (girls’) manga. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015464242/en/ (left) (C) Moto Hagio / Shogakukan ; (center) (C) Ryoko Yamagishi ; (right) (C) Waki Yamato / Kodansha Moto Hagio, Ryoko […]
-
October 26, 2026
Coincheck Group N.V. to Announce Second Quarter 2027 Financial Results on November 9, 2026
Oct. 26, 2026 12:00 UTC Coincheck Group N.V. to Announce Second Quarter 2027 Financial Results on November 9, 2026 AMSTERDAM–(BUSINESS WIRE)– Coincheck Group N.V. (NASDAQ: CNCK), a Dutch limited liability company that provides digital asset trade execution, custody, staking and asset management services, today announced that it plans to release its financial results for the quarter ended September 30, 2026, on Monday, November 9, 2026. The company will host a conference call to discuss the quarter at 5:00 pm ET that same day. Hosting the call will be Pascal St-Jean, Chief Executive Officer, and Jason Sandberg, Chief Financial Officer. The live webcast of the earnings conference call can be accessed […]
-

October 23, 2026
Striding AI Unveils Physical AI Solution for 24/7 Retail at APRCE 2026
Oct. 23, 2026 13:00 UTC Striding AI Unveils Physical AI Solution for 24/7 Retail at APRCE 2026 SINGAPORE–(BUSINESS WIRE)– On October 8, 2026, Striding AI unveiled its Physical AI solution for retail, including two self-developed robots and a robot management platform, at the 22nd Asia-Pacific Retailers Convention & Exhibition (APRCE 2026). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021654893/en/ Song Yao, Founder and CEO of Striding AI, is delivering the speech Designed for human-robot collaboration in real-world retail environments, the solution automates carrying, shelf replenishment, inventory checks, and patrols, allowing employees to focus on customer service. Robots can also undertake repetitive overnight work, reducing the need for […]
-
October 23, 2026
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study
Oct. 23, 2026 11:30 UTC Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026 Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric Cancer Findings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)– […]
-
October 23, 2026
Nidec Discloses an English Version of the Digest of the Executive Responsibility Investigation Committee’s Investigation Report
Oct. 23, 2026 05:04 UTC Nidec Discloses an English Version of the Digest of the Executive Responsibility Investigation Committee’s Investigation Report KYOTO, Japan–(BUSINESS WIRE)– As announced in the press release, “Nidec Discloses the Investigation Report Issued by the Executive Responsibility Investigation Committee,” dated October 20, 2026, Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) hereby discloses an English version of the digest of the Executive Responsibility Investigation Committee’s investigation report as shown in the attachment, as the translation was completed today. Please see the full release here: https://www.release.tdnet.info/inbs/ek/140120261022554890.pdf View source version on businesswire.com: https://www.businesswire.com/news/home/20261022183149/en/ Contacts Teruaki Urago General Manager Investor Relations +81-75-935-6140 ir@nidec.com Source: Nidec Corporation View this news release online at: […]
-
October 23, 2026
ADVASA Announces Proposed Share Forfeiture by Largest Stockholder
Oct. 22, 2026 20:21 UTC ADVASA Announces Proposed Share Forfeiture by Largest Stockholder Proposed cancellation would reduce outstanding common stock by approximately 20% TOKYO & NEW YORK–(BUSINESS WIRE)– Advasa Holdings, Inc. (Nasdaq: ADBT) (“ADVASA” or the “Company”), a fintech payment holding company delivering Earned Wage Access (“EWA”) and financial infrastructure solutions, today announced that Mr. Asamitsu Kosugi, the Company’s largest stockholder, has expressed his intention to surrender to the Company, for no consideration, 97,413,140 shares of the Company’s common stock, representing approximately 20% of the Company’s total outstanding common stock. Proposed Forfeiture Under the transaction, Mr. Asamitsu Kosugi, the Company’s largest stockholder, has advised The Company that he will surrender […]
-

October 22, 2026
Otsuka Presents Landmark Final Phase 3 VISIONARY Results at ASN Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilized Kidney Function and Reduced Risk of Disease Progression and Kidney Failure, Redefining Treatment Paradigm in IgA Nephropathy
Oct. 22, 2026 14:03 UTC Otsuka Presents Landmark Final Phase 3 VISIONARY Results at ASN Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilized Kidney Function and Reduced Risk of Disease Progression and Kidney Failure, Redefining Treatment Paradigm in IgA Nephropathy Results from the Phase 3 VISIONARY trial showed a 97.1% reduction in the risk of a composite kidney outcome event of kidney function decline or kidney failure in patients treated with VOYXACT compared with placebo over two years. VISIONARY demonstrated sustained preservation of kidney function across all prespecified subgroups over two years, supporting the findings previously reported in the entire study population and confirming the role of selective APRIL inhibition as a disease-modifying treatment […]
-

October 22, 2026
SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age
Oct. 22, 2026 13:00 UTC SBC Medical Initiates Development of a DNA Methylation Test to Estimate Biological Age Leveraging the Waqoo Group’s research and technology ecosystem to establish a new personal baseline for proactive health and longevity IRVINE, Calif.–(BUSINESS WIRE)– SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that it has commenced in-house development of a test designed to estimate an individual’s biological age using DNA methylation analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022474590/en/ SBC Medical Initiates Development of a DNA Methylation Test to […]